ArticleResearch and practice in thrombosis and haemostasis2024

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.

Andrew D Leavitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.